Southwest Oncology Group Study S0530: a phase 2 trial of clofarabine and cytarabine for relapsed or refractory acute lymphocytic leukaemia.
Clofarabine and cytarabine target different steps in DNA synthesis and replication, are synergistic in vivo, and have non-overlapping toxicities, making this combination a potentially promising treatment for acute lymphocytic leukaemia. Thirty-seven patients were treated. The median age was 41 years, 44% of patients were either in ≥2nd relapse or had refractory disease and 59% of patients had poor risk cytogenetics. Six out of 36 patients (17%) achieved a complete remission with or without complete count recovery; median overall survival was 3 months. Nucleoside transporter expression did not predict outcome. This regimen lacked sufficient activity to warrant further testing.
Hematologic Oncology and Blood Disorders, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH 44195, USA. advania@ccf.org
Anjali S
AS
Advani
Holly M
HM
Gundacker
Olga
O
Sala-Torra
Jerald P
JP
Radich
Raymond
R
Lai
Marilyn L
ML
Slovak
Jeffrey E
JE
Lancet
Steve E
SE
Coutre
Robert K
RK
Stuart
Martha P
MP
Mims
Patrick J
PJ
Stiff
Frederick R
FR
Appelbaum
D000227:Adenine Nucleotides / Q000008:administration & dosage / Q000009:adverse effects; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001087:Arabinonucleosides / Q000008:administration & dosage / Q000009:adverse effects; D000077866:Clofarabine; D055513:Connective Tissue Growth Factor / Q000097:blood; D003561:Cytarabine / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D006801:Humans; D008297:Male; D009363:Neoplasm Proteins / Q000097:blood; D033703:Nucleoside Transport Proteins / Q000378:metabolism; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000097:blood / Q000188:drug therapy*; D011379:Prognosis; D012008:Recurrence; D016896:Treatment Outcome
D000227:Adenine Nucleotides; D001087:Arabinonucleosides; C526317:CCN2 protein, human; D009363:Neoplasm Proteins; D033703:Nucleoside Transport Proteins; D003561:Cytarabine; D055513:Connective Tissue Growth Factor; D000077866:Clofarabine